Clinical trial · Interventional
Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies
Clinical Study of Cord Blood Derived CAR-T Cells in Patients With Refractory/Relapsed B Cell Leukemia/Lymphoma Who Are Failed for Autologous CAR-T Cells or Autologous CAR-T Can Not be Prepared
NCT03881774CI-TRIAL-00037719unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluation the safety and efficacy of cord blood-derived CAR-T cells in patients with relapsed/refractory B cell leukemia/lymphoma whose disease relapsed after autologous CAR-T cells therapy or who fail to preparation for autologous CAR-T cells
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| B Cell Leukemia | Chronic Lymphocytic Leukemia | ALIAS | 0.90 |
| B Cell Lymphoma | B-Cell Malignant Neoplasm | CURATED_BROADER | 0.80 |
| Refractory | — | UNRESOLVED | — |
| Relapsed | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CAR-T cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- experimental arm
- description
- cord blood derived CAR T cells group
- interventionNames
- Biological: CAR-T cells
Primary outcomes (1)
- measure
- occurrence of study related adverse events
- timeFrame
- one year
- description
- safety of CAR-T cells
Secondary outcomes (4)
- measure
- objective response rate
- timeFrame
- three months
- description
- the proportion of patients with CR or PR
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 4 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * expected lifespan \>3 months * patients with refractory/relapsed B cell leukemia/lymphoma whose diseases relapse after autologous CAR-T cells or the preparation for autologous CAR-T cells fails * KPS \>70 * for patients with lymphoma, at least one measurable lesion according to RECIST 1.1 * enough function of heart, liver, kidney and bone marrow * no history of severy allergy * no other serious diseases that conflict with this plan * no other history of malignancy * no serious mental illness * patients and their families members agree to participate in this clinical study and sign the Informed Consent Form Exclusion Criteria: * pregnant or lactating women * vevere infectious or viral diseases * active hepatitis B or C viral hepatitis * Patients who have used large amounts of glucocorticoids or other immunosuppressive agents within the last 4 weeks * participated in other clinical studies in the past 3 months or who have been treated with other gene products; * others that other investigators consider not suitable for this clinical study
References
Publications (0)
Data not yet available
No reference posted for this study.